Odds of Hospitalization for COVID-19 After 3 vs 2 Doses of mRNA COVID-19 Vaccine by Time Since Booster Dose

Article Biochemistry & Molecular Biology

Effectiveness of COVID-19 booster vaccines against COVID-19-related symptoms, hospitalization and death in England

Nick Andrews et al.

Summary: This study examined the relative and absolute effectiveness of mRNA booster vaccination against COVID-19. The results showed that the booster dose of BNT162b2 or mRNA-1273 had a relative effectiveness ranging from 85% to 95% against symptomatic disease, and an absolute effectiveness ranging from 94% to 97%. For hospitalization or death, the absolute effectiveness of the BNT162b2 booster ranged from 97% to 99% in all age groups. The study provides real-world evidence of significantly increased protection from the booster vaccine dose against mild and severe disease.

NATURE MEDICINE (2022)

添加到收藏夹

Article Immunology

Relative Vaccine Effectiveness of a Severe Acute Respiratory Syndrome Coronavirus 2 Messenger RNA Vaccine Booster Dose Against the Omicron Variant

Adeel A. Butt et al.

Summary: While the relative vaccine effectiveness of a booster dose of the COVID-19 mRNA vaccine in preventing infection against the Omicron variant is low, it is substantial in preventing hospitalization and high in preventing the most severe/critical disease.

CLINICAL INFECTIOUS DISEASES (2022)

添加到收藏夹

Letter Medicine, General & Internal

Effectiveness of Homologous and Heterologous Covid-19 Boosters against Omicron

Emma K. Accorsi et al.

Summary: The study assessed the protection against the omicron variant in individuals vaccinated with the adenovirus-based vaccine and received a booster dose of an mRNA vaccine. It was found that a single booster dose of an mRNA vaccine provided protection close to that of a three-dose mRNA vaccine regimen in recipients of the initial dose of Ad26.COV2.S.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

添加到收藏夹

Article Critical Care Medicine

Comparative vaccine effectiveness against severe COVID-19 over time in US hospital administrative data: a case-control study

Bill J. Wright et al.

Summary: Research suggests that the protection offered by COVID-19 vaccines may decline after 200 days, especially for older patients or those with specific comorbidities. Therefore, booster vaccinations may be necessary for everyone, but especially for these populations.

LANCET RESPIRATORY MEDICINE (2022)

添加到收藏夹

Article Critical Care Medicine

Durability of BNT162b2 vaccine against hospital and emergency department admissions due to the omicron and delta variants in a large health system in the USA: a test-negative case-control study

Sara Y. Tartof et al.

Summary: This study evaluated the effectiveness and durability of two and three doses of the BNT162b2 (Pfizer-BioNTech) mRNA vaccine against hospital and emergency department admissions due to the delta and omicron variants. The results showed that three doses of the vaccine provided high protection against both variants in the first 3 months after vaccination, but waning was observed against the omicron variant after 3 months. Additional doses of vaccines might be needed to maintain high levels of protection against future variants.

LANCET RESPIRATORY MEDICINE (2022)

添加到收藏夹

Odds of Hospitalization for COVID-19 After 3 vs 2 Doses of mRNA COVID-19 Vaccine by Time Since Booster Dose

相关参考文献

Effectiveness of COVID-19 booster vaccines against COVID-19-related symptoms, hospitalization and death in England

Relative Vaccine Effectiveness of a Severe Acute Respiratory Syndrome Coronavirus 2 Messenger RNA Vaccine Booster Dose Against the Omicron Variant

Effectiveness of Homologous and Heterologous Covid-19 Boosters against Omicron

Comparative vaccine effectiveness against severe COVID-19 over time in US hospital administrative data: a case-control study

Durability of BNT162b2 vaccine against hospital and emergency department admissions due to the omicron and delta variants in a large health system in the USA: a test-negative case-control study

导出引文

分享论文